Antigenics Inc represents a strong commitment to advancing innovative immunotherapies. With a focus on developing personalized treatment options, the company aims to address the unmet medical needs of patients. Antigenics Inc values scientific excellence and collaboration to drive groundbreaking research and development initiatives. By leveraging cutting-edge technologies and strategic partnerships, the company strives to improve patient outcomes and enhance quality of life. Emphasizing a patient-centric approach, Antigenics Inc is dedicated to providing hope and solutions for those affected by serious diseases.

Antigenics Inc is primarily present in the United States.

Antigenics Inc has achieved several significant milestones over the years. One notable accomplishment is the FDA approval of their therapeutic vaccine, Oncophage, in 2010. This vaccine is designed to stimulate the body's immune response against cancer cells, offering a personalized treatment approach for each patient. Additionally, Antigenics Inc has successfully conducted clinical trials, demonstrated positive results, and developed a strong intellectual property portfolio. These achievements highlight the company's dedication to advancing immunotherapies and their commitment to improving patient outcomes in the field of oncology.

Antigenics Inc., now known as Agenus Inc., is a biotechnology company that focuses on the discovery, development, and commercialization of immunotherapies for the treatment of cancer and other diseases. Founded in 1994, Antigenics Inc. has a rich history of advancing innovative and personalized therapies that harness the power of the immune system. Over the years, the company has made significant contributions to the field of immuno-oncology and has built a strong portfolio of proprietary platforms and technologies. Antigenics Inc., now Agenus, continues to strive towards developing breakthrough treatments and improving patient outcomes in the fight against cancer.

The main competitors of Antigenics Inc in the market are other companies in the biotechnology industry such as Progenics Pharmaceuticals, Inc., Agenus Inc., and Celldex Therapeutics, Inc.

Antigenics Inc primarily operates in the biotechnology and pharmaceutical industries.

The business model of Antigenics Inc is focused on the research, development, and commercialization of innovative immunotherapeutic products for the treatment of various diseases. Antigenics Inc aims to leverage its expertise in antigen discovery, vaccine development, and immune-based therapies to bring about significant advancements in the field of healthcare. Through strategic partnerships and collaborations, the company aims to create and enhance value for its shareholders by successfully navigating the complex landscape of drug discovery and development. Antigenics Inc strives to address unmet medical needs and improve patient outcomes through the advancement of its therapeutic candidates.

KGV ไม่สามารถคำนวณได้สำหรับ Antigenics ในขณะนี้

ขณะนี้ไม่สามารถคำนวณ KUV สำหรับ Antigenics ได้

AlleAktien คุณภาพสกอร์สำหรับ Antigenics คือ 4/10.

ขณะนี้ไม่สามารถคำนวณยอดขายสำหรับ Antigenics ได้

ขณะนี้ไม่สามารถคำนวณกำไรสำหรับ Antigenics ได้

Antigenics Inc. is a biotechnology company specializing in the development and commercialization of immunotherapies for cancer and infectious diseases. The company is based in New York City and has offices in Europe and Asia. Antigenics Inc. specializes in the development of individualized immunotherapies for patients with advanced cancer. The company has a proprietary platform technology called A-Ox-HPV, which is based on the use of heat-inactivated Staphylococcus aureus (HISA). This technology allows for the development of personalized cancer vaccines for each patient, containing specific antigenic proteins of the tumor. Antigenics Inc. has conducted Phase II clinical trials for various types of cancer, including lung cancer, colorectal cancer, and prostate cancer. Antigenics Inc. has also developed a unique platform technology called QS-21, which can be used as an adjuvant for a variety of vaccines. QS-21 enhances the ability of the immune system to respond to a range of antigens. Antigenics has sublicensed this technology to other biotech and pharmaceutical companies. In addition to immunotherapies for cancer, Antigenics Inc. has also developed a range of products for the diagnosis and treatment of infectious diseases. The company has granted CEL-SCI Corporation exclusive license rights to use the HISA technology for the production of vaccines for infectious diseases such as Ebola and MERS-CoV. Antigenics Inc. also operates a business unit called AgroBioSciences, which specializes in the development of technologies for agriculture. This business unit uses the QS-21 technology to develop vaccines for livestock and plants. Antigenics Inc.'s business model is based on the development and commercialization of immunotherapies for cancer and infectious diseases, as well as the licensing of its platform technologies to other biotech and pharmaceutical companies. The company generates revenue from conducting clinical trials, selling products, and licensing its technologies. Antigenics Inc. is an innovative biotechnology company specializing in the development of individualized immunotherapies for cancer and infectious diseases. The company has a promising pipeline of immunotherapy candidates and platform technologies that allow it to maximize the potential of its products and have a significant impact on healthcare.

Antigenics จ่ายเงินปันผล 0 USD ผ่าน ครั้งในหนภายในหนึ่งปี.

ปัจจุบันไม่สามารถคำนวณเงินปันผลสำหรับ Antigenics หรือบริษัทไม่จ่ายเงินปันผล.

ISIN ของ Antigenics คือ US0370311013

WKN ของ Antigenics คือ 932075.

ตัวย่อของ Antigenics คือ ANTI

ภายในช่วง 12 เดือนที่ผ่านมา Antigenics จ่ายเงินปันผลทั้งหมด นี้เทียบเท่ากับอัตราผลตอบแทนจากเงินปันผลประมาณ สำหรับ 12 เดือนข้างหน้า Antigenics คาดว่าจะจ่ายเงินปันผลทั้งหมด 0 USD

อัตราผลตอบแทนเงินปันผลของ Antigenics ในปัจจุบันคือ

Antigenics จ่ายเงินปันผลทุกไตรมาส การจ่ายเงินปันผลจะเกิดขึ้นในเดือน

Antigenics จ่ายเงินปันผลทุกปีในช่วง 0 ปีที่ผ่านมา.

คาดว่าในช่วง 12 เดือนข้างหน้าจะมีการจ่ายเงินปันผลทั้งหมด 0 USD ซึ่งเทียบเท่ากับผลตอบแทนจากเงินปันผลร้อยละ 0 %

Antigenics ถูกจัดให้อยู่ในภาคส่วน '—'

เพื่อรับเงินปันผลล่าสุดของ Antigenics ในวันที่ 12/7/2568 ที่มูลค่า 0 USD คุณจะต้องถือหุ้นไว้ในพอร์ตก่อนวันที่เป็น Ex-Tag ในวันที่ 12/7/2568

การจ่ายเงินปันผลครั้งล่าสุดเกิดขึ้นเมื่อวันที่ 12/7/2568

ในปี 2024 บริษัท Antigenics ได้จ่ายเงินปันผลเป็นจำนวน 0 USD

เงินปันผลของ Antigenics จะถูกจ่ายใน USD